Biotech & Pharma

STAT+: Pharmalittle: We're reading about an AstraZeneca trial failure, a 'monstrous' conflict of interest, and more

26 sec read7 views0 listens

AstraZeneca's heart disease trial for its experimental drug failed, showing no additional benefits for patients already on stabilizer drugs. This setback highlights challenges in a competitive market and underscores the difficulty of improving outcomes for patients with progressive conditions like ATTR-CM. Developers should monitor AstraZeneca’s response to this failure and any potential impacts on future clinical trials in similar therapeutic areas.

Read the full article at STAT Pharma

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Tech & Gadgets10 hours ago25 sec read

How Toronto is using Clariti's AI to speed up building permit approvals

Toronto has launched a one-year pilot program with Clariti's CivCheck AI software to expedite the city's building permit approval process. This initiative aims to reduce delays caused by incomplete applications, which can add significant costs for de...

Ali Nemati

Biotech & Pharma14 hours ago28 sec read

CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial

A Phase 1 clinical trial at Charité—Universitätsmedizin Berlin has shown that CAR T-cell therapy significantly reduced disease activity in six patients with severe, treatment-refractory rheumatoid arthritis (RA), with three achieving sustained remiss...

Ali Nemati

Biotech & Pharma1 day ago23 sec read

Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer

Aprea Therapeutics is accelerating enrollment in its Phase I trial of APR-1051, a WEE1 kinase inhibitor, after observing early signs of clinical activity. This expansion aims to gather more data on the drug's efficacy and safety, particularly for pat...

Ali Nemati